The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
What is the source please?
GL.
Revenue is forecast to grow 202.63% per year
...agree the shares should easily be 20-30p on the back of the Thermo Fischer deal alone, with only positive news catalysts likely ahead, though the issue may be the company is just too small and illiquid for specialist sector funds to care at this point? So it may be down to us retail and the existing insto fund investors to hoover up the shares before they get acquired sometime in 2024/25. Any material revenue/testing traction in the meantime, will also help the shares re-rate higher.
I added more at 8p on Monday, my average is still under water but not for long!
Got to be one of the most underrated aim shares. Shirley
Hopefully a nice strong finish to year end. Update on finalised rates due any day
Agree with accepted commercial tests in the USA I never understood why it was so undervalued!?
GL.
This is on its way to 30p as it should be.
Well somebody is slowly racking up the 100k buys. More of a 10k buyer myself!
How under the radar is this still . Good day ,lots more to come atb
(mrkcap £13m) fit into this camp, reflecting positive fundamentals and continued strong execution.
In fact today, Verici announced that a leading US medical publication, The American Journal of Transplantation, had confirmed that its flagship post-surgery test Tutivia "demonstrates strong performance in the assessment of risk of acute rejection following kidney transplant". This is especially important for doctors during the first few weeks post-graft, when patient management can be complex and other biomarkers are contraindicated or less informative.
This milestone represents not only another major endorsement of the quality of
VRCI
’s medical science, but also a further crucial step in the commercialisation of Tutivia. As the company builds industry trust and recognition, it continues to gain local coverage determination (LCD) for Medicare reimbursement - which should in turn increase usage and transplant centre adoption.
Dr. Lorenzo Gallon, Chair of Scientific Advisory Board of Verici Dx commented: "I am delighted that the data from our pivotal validation study for Tutivia has been published in such a high-impact and prestigious journal as The American Journal of Transplantation."
CMO Dr Michael Donovan, DMD, added: "This publication further validates the benefits of the test for kidney transplant patients and their clinicians, and demonstrates the comprehensive design of the study to reflect the full clinical continuum."
COO Patti Connolly, concluded: "We are already seeing growing clinical interest, and as this publication is key in the application for LCD coverage, we anticipate an accelerated adoption of Tutivia within the medical community, marking a significant step forward in enhancing diagnostic accuracy and post-transplant patient care."
Finally regarding financials, Singer Capital Markets are anticipating revenues to jump from $0.3m in FY23 to $8.6m next year while delivering an adjusted EBITDA of $0.1m in 2024 and closing Dec'23 with net cash of $0.1m. They have a BUY rating with a 30p target price.
VRCI
shares jumped 13% on today's announcement.
'The strong results were particularly noteworthy given that the study utilised a generalised 'all-comers' patient population rather than a specific subgroup and examined performance in both the for-cause and surveillance settings. The study was purposefully designed this way to capture the clinical reality across 13 international transplant centres in five countries. As a result, the data reflects the wide clinical applicability of Tutivia? for comprehensive commercial adoption in a real-world setting.'
GL.
Great strides in commercialisation!
This has to take off at some time surely!
GL.
Another great Rns
Welcome to aim. Market makers innit
Why's my 8000 buy showing as a sell?
Great news!
Opens the doorway for deeper relations with Thermo Fisher and also other JV/collaborations!
GL.
Great rns people should be very interested in this share
A distinct lack of interest it seems. For now
This ain’t going to well
I was in work so was watching but never got all the detail, however I didn't hear anything that we haven't heard before. More of a confirmation the company is on the right path although did mention possibility of more deals with Thermo in time. I don't expect the share price to go up massively on the back of it.
Would love to be wrong of course.
I can't really remember much it was just her tone I picked up on. It's not going to have explosive growth but its going to be big was the nub of it.
Spill the beans then 🤔
Mmm. That was a very confident woman.
It would make sense to have an investor call alongside confirmations of the median rate for both Tutivia and Clarava. And the commercial use of the latter ahead of the call.
I missed the 9am deadline, but hopefully if no RNS tomorrow they will confirm these are still objectives for 2023.